StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Strensiq (asfotase alfa) by Quarter

Strensiq (asfotase alfa) — Emerging Markets YoY actual (%) (%)

QuarterlyAnnual

AstraZeneca Strensiq (asfotase alfa): 2.0% in Q2 2026, down 63.0 pts from a year earlier.

Latest, Q2 2026
2.0%
Period ended Jun 30, 2026
Change on a year earlier
-63.0 pts
65.0% in Q2 2025
History
19 quarters
Since Q3 2021
Sources
19
Documents cited below

Where the Q2 2026 figure comes from

“|| Strensiq | | 536 | | 36 | | 36 | | 452 | | 42 | | 16 | | 2 | | 2 | | 37 | | 20 | | 14 | | 31 | | 7 | | 15”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStrensiq (asfotase alfa) — Emerging Markets YoY actual (%) (%)Year on yearSource
Q2 2026Jun 30, 20262.0%-63.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202644.0%-15.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q3 2025Sep 30, 202545.0%-7.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202565.0%+58.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202559.0%+15.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202431.0%+14.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202452.0%+84.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20247.0%+8.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202444.0%-26.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202317.0%-42.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-32.0%-105.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-1.0%-2.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202370.0%+5.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202259.0%-12.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202273.0%-14.0 ptsForm 6-K FY2022Q3 Earnings Release ↗
Q2 2022Jun 30, 20221.0%–Form 6-K FY2022Q2 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Strensiq (asfotase alfa) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-strensiq-em-act-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.